Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ocular Therapeutix, Inc. (NASDAQ: OCUL).

Full DD Report for OCUL

You must become a subscriber to view this report.


Recent News from (NASDAQ: OCUL)

Healthcare and financial stocks down in premarket trade
BGC Partners (NASDAQ: BGCP ) -32% . More news on: BGC Partners, Inc., Aphria Inc., Tonix Pharmaceuticals Holding Corp., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: December, 03 2018 09:17
Ocular Therapeutix(TM) Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery
DEXTENZA® (dexamethasone ophthalmic insert) is the First Intracanalicular Insert for Drug Delivery Ocular Therapeutix to Host Conference Call Today at 8:30 am ET Subhead of release should read: DEXTENZA® (dexamethasone ophthalmic insert) is the First Intracanalicular In...
Source: Business Wire
Date: December, 03 2018 07:00
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2018 Results - Earnings Call Transcript
Ocular Therapeutix, Inc. (OCUL) Q3 2018 Earnings Conference Call November 7, 2018 4:30 PM ET Executives Donald Notman - Chief Financial Officer Antony Mattessich - President and Chief Executive Officer Michael Goldstein - Chief Medical Officer Scott Corning - Senior Vice Presid...
Source: SeekingAlpha
Date: November, 07 2018 21:13
Ocular Therapeutix misses by $0.02, revenue in-line
Ocular Therapeutix (NASDAQ: OCUL ): Q3 GAAP EPS of -$0.38 misses by $0.02 . Revenue of $0.5M in-line (flat Y/Y). Cash and equivalents of $56.9M. Shares -17% . Press Release More news on: Ocular Therapeutix, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: November, 07 2018 16:24
Ocular Therapeutix(TM) Reports Third Quarter 2018 Financial Results and Business Update
DEXTENZA ® NDA Target PDUFA Action Date of December 28, 2018 Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today anno...
Source: Business Wire
Date: November, 07 2018 16:01
Ocular Therapeutix(TM) To Report Third Quarter 2018 Financial Results
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter ended September 30, 2018 financial res...
Source: Business Wire
Date: October, 31 2018 08:00
Ocular Therapeutix receives FDA warning letter related to ReSure Sealant
Ocular Therapeutix (NASDAQ: OCUL ) has received a warning letter from the FDA related to Ocular’s compliance with data collection and information reporting obligations in a post-approval Device Exposure Registry study required as a condition for approval of the premarket approval ap...
Source: SeekingAlpha
Date: October, 19 2018 08:31
Ocular Therapeutix(TM) Receives FDA Warning Letter Related to ReSure® Sealant
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the receipt of a warning letter from the U.S. Food and Drug Administration (FDA) ...
Source: Business Wire
Date: October, 19 2018 07:50
Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD - Discovering Underlying Factors of Influence
NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Teradata Corporation (NYSE:TDC), Liberty TripAdvisor Holdings, Inc. (N...
Source: GlobeNewswire
Date: October, 18 2018 08:55
Ocular Therapeutix: Critical FDA Date Up Ahead
There are crimes of passion and crimes of logic. The boundary between them is not clearly defined." - Albert Camus Today, we look at a small ocular concern with a critical FDA decision date fast approaching. Company Overview: Ocular Therapeutix, Inc. ( OCUL ) is a Bedford, Massachusett...
Source: SeekingAlpha
Date: October, 16 2018 15:32

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-125.905.736.005.71357,688
2018-12-115.865.836.055.7264506,068
2018-12-105.815.605.935.50738,749
2018-12-076.085.826.135.68693,664
2018-12-065.576.076.09735.501,039,804

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1271,585117,81160.7626Short
2018-12-1181,602135,47060.2362Short
2018-12-10114,536214,78653.3256Short
2018-12-07152,942212,87971.8446Short
2018-12-06187,813347,45954.0533Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OCUL.


About Ocular Therapeutix, Inc. (NASDAQ: OCUL)

Logo for Ocular Therapeutix, Inc. (NASDAQ: OCUL)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: OCUL)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 23 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 23 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 08 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 08 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 12 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 07 2018

       

       


      Daily Technical Chart for (NASDAQ: OCUL)

      Daily Technical Chart for (NASDAQ: OCUL)


      Stay tuned for daily updates and more on (NASDAQ: OCUL)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: OCUL)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OCUL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of OCUL and does not buy, sell, or trade any shares of OCUL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/